TD Cowen raises Exelixis' price target to $27.00 and maintains buy rating despite Q1 earnings miss.
TD Cowen raised its price target for biotech firm Exelixis (NASDAQ:EXEL) to $27.00 from $25.00 and reaffirmed its buy rating. The company reported a Q1 EPS of $0.12, missing expectations by $0.16, and revenue of $425.23M, below expectations of $461.04M. Despite the earnings miss, several brokerages, including HC Wainwright, TD Cowen, Stifel Nicolaus, JMP Securities, and TheStreet, maintain positive ratings on the stock.
May 04, 2024
3 Articles